🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests

Brain(2024)10.1093/brain/awae346Source: DataRank Database

A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests is a research paper published in Brain (2024). On theSindex it has a DataRank of 0. It has been cited 102 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access102 citations

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (78 grants)Impact (FWCI 29.77)OA: hybridTopics (60)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (24)

Gemma Salvadó ORCID,Shorena Janelidze ORCID,Niklas Mattsson ORCID,Divya Bali ORCID,Anna Orduña Dolado ORCID

Live enrichment

PubMed:39468767 PMC:PMC11788211 OpenAlex:https://openalex.org/W4403854232

National Institute of Aging

Grant: R01AG083740

European Research Council

Grant: ADG-101096455

Alzheimer’s Association

Grant: ZEN24-1069572

Alzheimer’s Association

Grant: SG-23-1061717

Swedish Research Council

Grant: 2022-00775

Swedish Research Council

Grant: 2021-02219

Swedish Research Council

Grant: #2023-00356

Swedish Research Council

Grant: #2022-01018

Swedish Research Council

Grant: #2019-02397

ERA PerMed

Grant: ERAPERMED2021-184

Knut and Alice Wallenberg Foundation

Grant: 2022-0231

Lund University

Grant: #R01AG070941

Lund University

Grant: #P30AG066444

Lund University

Grant: #P01AG003991

Lund University

Grant: #P01AG026276

Swedish Alzheimer Foundation

Grant: AF-980907

Swedish Alzheimer Foundation

Grant: AF-994229

Swedish Brain Foundation

Grant: FO2021-0293

Swedish Brain Foundation

Grant: FO2023-0163

Parkinson Foundation of Sweden

Grant: 1412/22

WASP and DDLS Joint call for research projects

Grant: WASP/DDLS22-066

Skåne University Hospital Foundation

Grant: 2020-O000028

Regionalt Forskningsstöd

Grant: 2022-1259

Swedish federal government under the ALF agreement

Grant: 2022-Projekt0080

Swedish federal government under the ALF agreement

Grant: 2022-Projekt0107

Swedish federal government under the ALF agreement

Grant: P30AG066444

Swedish federal government under the ALF agreement

Grant: P01AG03991

Swedish federal government under the ALF agreement

Grant: P01AG026276

Marie Sklodowska-Curie

Grant: 101061836

Accurate diagnosis and prognosis of Alzheimer’s disease in primary care

Alzheimer’s Association Research Fellowship

Grant: AARF-22-972612

Alzheimerfonden

Grant: AF-980942

Alzheimer’s Association Research Fellowship

Grant: AARF-16-443265

National Institutes of Health

Grant: R01AG044546

National Institutes of Health

Grant: P01AG003991

National Institutes of Health

Grant: RF1AG053303

National Institutes of Health

Grant: RF1AG058501

National Institutes of Health

Grant: U01AG058922

National Institutes of Health

Grant: RF1AG074007

Department of Defense

Grant: LI- W81XWH2010849

Alzheimer’s Association Zenith Fellows Award

Grant: ZEN-22-848604

European Union’s Horizon Europe research and innovation programme

Grant: 101053962

Fluid Biomarkers for Neurodegenerative Dementias

Swedish State Support for Clinical Research

Grant: #ALFGBG-71320

European Research Council

Grant: 101096455

Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease

NIA NIH HHS

Grant: R01 AG070941

National Institutes of Health

Grant: 5P01AG026276-07

Antecedent Neuroimaging Biomarkers

National Institutes of Health

Grant: 5P01AG003991-38

Healthy Aging and Senile Dementia

National Institutes of Health

Grant: 3RF1AG053303-01S1

USING QUANTITATIVE TRAITS TO IDENTIFY NOVEL GENES FOR ALZHEIMERS DISEASE AND OTHER COMPLEX TRAITS

National Institutes of Health

Grant: 1P30AG066444-01

Alzheimer's Disease Research Center

National Institutes of Health

Grant: 5R01AG044546-03

IDENTIFYING RARE VARIANTS THAT INCREASE RISK FOR ALZHEIMER'S DISEASE

Knut and Alice Wallenberg Foundation

Grant: unidentified

unidentified

National Institutes of Health

Grant: 1RF1AG074007-01

Sex-specific Molecular Profiling to Understand Pathology and Identify Causal Genes and Drug Targets for Alzheimer's Disease

National Institutes of Health

Grant: 5R01AG083740-02

Prospective validation and implementation of high-performing blood biomarkers and digital cognitive tests for detection of Alzheimer's disease in specialist memory clinic and primary care settings

National Institutes of Health

Grant: 5R01AG070941-02

Staging Alzheimer disease with blood-based biomarkers

National Institutes of Health

Grant: 5U01AG058922-05

The Familial Alzheimer Sequencing (FASe) Project

National Institutes of Health

Grant: 1RF1AG058501-01

GENETIC MODIFIERS OF CEREBROSPINAL FLUID TREM2 IN ALZHEIMER'S DISEASE

Cure Alzheimer’s Fund

Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse

Washington University School of Medicine

Chan Zuckerberg Initiative

Departments of Neurology and Psychiatry

Roche

Cure Alzheimer's Fund

European Union’s Horizon 2020 Research and Innovation Program

Coins for Alzheimer’s Research Trust

GE Healthcare

Greta och Johan Kocks

Strategic Research Area MultiPark

Wallenberg Scholar

anonymous foundation

European Union's Horizon 2020 Research and Innovation Program

GHR Foundation

Hope Center for Neurological Disorders

Knight ADRC Developmental Projects

Neurogenomics and Informatics Center

Rönström Family Foundation

Tracy Family SILQ Center

Coins for Alzheimer's Research Trust

Michael J. Fox Foundation

FWCI

29.77

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://academic.oup.com/brain/advance-article-pdf/doi/10.1093/brain/awae346/60184230/awae346.pdf

publisherhttps://academic.oup.com/brain/advance-article-pdf/doi/10.1093/brain/awae346/60184230/awae346.pdf

publisherhttps://academic.oup.com/brain/advance-article-pdf/doi/10.1093/brain/awae346/61196593/awae346.pdf

publisherhttps://academic.oup.com/brain/article-pdf/148/2/416/61196593/awae346.pdf

journalhttps://doi.org/10.1093/brain/awae346

Fields of Study

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsFrailty in Older Adults0303 health sciences03 medical and health sciences

MeSH Terms

AdultAgedAged, 80 and overAlzheimer DiseaseCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedPhosphorylationSwedenCohort StudiesBiomarkersAmyloid beta-Peptidestau ProteinsPositron-Emission TomographyYoung AdultCognitive Dysfunction

Keywords

BiomarkerCerebrospinal fluidInternal medicineMedicineAmyloid βOncologyGastroenterologyNuclear medicinePathologyChemistryDiseaseBiochemistryAlzheimer’s diseasePlasma BiomarkersCsf BiomarkersP-tau217MaleAged, 80 and overAdultSwedenAmyloid beta-Peptidestau ProteinsMiddle AgedArticleCohort StudiesYoung AdultCross-Sectional StudiesAlzheimer DiseasePositron-Emission TomographyHumansOriginal ArticleFemaleLongitudinal StudiesPhosphorylationBiomarkersAged

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (10)

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

N/A

0.961DataRank · unranked

The Lancet Neurology(2021)

co-cited

10.1016/s1474-4422(21)00214-3

Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline

Alzheimer s & Dementia(2021)

co-cited

10.1002/alz.12415

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring

Nature Medicine(2022)

co-cited

10.1038/s41591-022-02074-w

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Nature Medicine(2022)

co-cited

10.1038/s41591-022-01925-w

Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease

Alzheimer s & Dementia(2023)

co-cited

10.1002/alz.13026

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

Alzheimer s & Dementia(2024)

co-cited

10.1002/alz.13859

Head‐to‐head comparison of leading blood tests for Alzheimer's disease pathology

Alzheimer s & Dementia(2024)

co-cited

10.1002/alz.14315

Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease

Alzheimer s Research & Therapy(2024)

co-cited

10.1186/s13195-024-01513-9

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid

Alzheimer s & Dementia(2024)

co-cited

10.1002/alz.13764

Alzheimer's Association Clinical Practice Guideline on the use of blood‐based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings

Alzheimer s & Dementia(2025)

co-cited

10.1002/alz.70535